STAAR SURGICAL CO - 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for STAAR SURGICAL CO for the period ended July 4, 1997. The company manufactures and sells ophthalmic products, including foldable intraocular lenses (IOLs), implantable contact lenses (ICL), and glaucoma implants. The company operates globally with significant export sales to Europe, Australia, and Southeast Asia.
Key Financial Metrics
| Metric | Six Months Ended July 4, 1997 | Six Months Ended June 28, 1996 |
|---|---|---|
| Total Revenues | $22,138,779 | $19,856,122 |
| Gross Profit | $16,983,915 (76.7% margin) | $15,140,214 (76.2% margin) |
| Operating Income | $5,613,417 (25.4% margin) | $4,526,441 (22.8% margin) |
| Net Income | $3,702,634 | $3,243,081 |
| Diluted EPS | $0.27 | $0.23 |
| Cash and Equivalents | $4,012,683 | $3,872,336 |
| Net Cash from Operations | $3,472,567 | $2,984,993 |
| Total Debt (Current + Long-term) | $6,480,093 | $N/A (See Note 4) |
| Current Ratio | 3.8:1 | 2.1:1 (Jan 3, 1997) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 11.5% year-over-year. International sales rose 22.4% due to demand for foldable IOLs and new product commercialization (Glaucoma Wick, ICL). U.S. sales increased 7.5% driven by volume, partially offset by a 5.4% price decrease.
- Profitability: Operating income increased 24.0% to $5.6 million. Gross margin improved slightly to 76.7% due to operating efficiencies, despite a shift to more expensive-to-manufacture products.
- Debt Restructuring: In June 1997, the company renegotiated its line of credit, increasing capacity to $10 million and reclassifying $4.2 million of debt from short-term to long-term. This significantly improved the current ratio from 2.1 to 3.8.
- Equity Position: The company eliminated its accumulated deficit, recording positive retained earnings of $1.1 million as of July 4, 1997.
Outlook, Risks, and Management Commentary
- Product Pipeline: Subsequent to the quarter, the company received European "CE Mark" approval for its toric IOL, ICL, Glaucoma Wick, and StaarVisc. Phase I clinical trials for the ICL were completed, with FDA approval to begin Phase II.
- Strategic Moves: The company acquired a European distributor of ophthalmic products during the quarter.
- Liquidity: Management expects future cash flow needs to be met by operations or additional financing. Cash decreased by $2.5 million during the period primarily due to debt repayments and inventory buildup for new product rollouts.
- Risks: International operations expose the company to exchange rate fluctuations, foreign government regulations, and political instability. The company relies on the commercial success of new products like the ICL and Glaucoma Wick.
Investor Verification Checklist
- Verify the sustainability of the 22.4% international sales growth and the impact of the new European distributor acquisition.
- Monitor the progress of Phase II clinical trials for the Implantable Contact Lens (ICL) and regulatory approvals in the U.S.
- Assess the impact of the 5.4% price decrease in the U.S. market on future gross margins.
- Confirm the company's ability to maintain the financial covenants required by the new $10 million line of credit.
- Review the inventory buildup ($13.4 million) to ensure it aligns with actual sales velocity for new products.